Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.2
(1.15%)
INR 13.2
(1.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.02 Billion INR | 25.91% |
| 2022 | 3.98 Billion INR | 1.94% |
| 2021 | 3.91 Billion INR | 11.11% |
| 2020 | 3.52 Billion INR | 8.65% |
| 2019 | 3.24 Billion INR | 13.09% |
| 2018 | 2.86 Billion INR | 7.95% |
| 2017 | 2.65 Billion INR | 1.65% |
| 2016 | 2.61 Billion INR | -14.18% |
| 2015 | 3.04 Billion INR | -27.05% |
| 2014 | 4.17 Billion INR | -26.79% |
| 2013 | 5.69 Billion INR | 44.94% |
| 2012 | 3.93 Billion INR | 0.0% |
| 2010 | 8.76 Billion INR | 27.13% |
| 2009 | 6.89 Billion INR | 16.15% |
| 2008 | 5.93 Billion INR | 14.32% |
| 2007 | 5.19 Billion INR | 36.73% |
| 2006 | 3.79 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.13 Billion INR | -15.81% |
| 2023 FY | 5.02 Billion INR | 25.91% |
| 2023 Q4 | 1.35 Billion INR | 31.86% |
| 2023 Q3 | 1.02 Billion INR | -11.52% |
| 2023 Q2 | 1.15 Billion INR | -21.96% |
| 2023 Q1 | 1.48 Billion INR | 58.33% |
| 2022 Q4 | 938.12 Million INR | -11.98% |
| 2022 Q3 | 1.06 Billion INR | 2.67% |
| 2022 Q2 | 1.03 Billion INR | 9.66% |
| 2022 Q1 | 946.74 Million INR | -4.51% |
| 2022 FY | 3.98 Billion INR | 1.94% |
| 2021 Q3 | 1.04 Billion INR | 7.16% |
| 2021 Q1 | 904.21 Million INR | 0.34% |
| 2021 Q2 | 973.74 Million INR | 7.69% |
| 2021 FY | 3.91 Billion INR | 11.11% |
| 2021 Q4 | 991.49 Million INR | -4.99% |
| 2020 FY | 3.52 Billion INR | 8.65% |
| 2020 Q1 | 613.12 Million INR | -21.51% |
| 2020 Q2 | 959.8 Million INR | 56.54% |
| 2020 Q3 | 1.04 Billion INR | 9.14% |
| 2020 Q4 | 901.14 Million INR | -13.98% |
| 2019 FY | 3.24 Billion INR | 13.09% |
| 2019 Q3 | 957.38 Million INR | 15.88% |
| 2019 Q4 | 781.19 Million INR | -18.4% |
| 2019 Q1 | 676.49 Million INR | -5.01% |
| 2019 Q2 | 826.17 Million INR | 22.13% |
| 2018 FY | 2.86 Billion INR | 7.95% |
| 2018 Q3 | 641.08 Million INR | -11.77% |
| 2018 Q4 | 712.19 Million INR | 11.09% |
| 2018 Q2 | 726.61 Million INR | -9.93% |
| 2018 Q1 | 806.72 Million INR | 24.57% |
| 2017 Q4 | 647.61 Million INR | -15.67% |
| 2017 Q1 | 526.08 Million INR | -9.46% |
| 2017 FY | 2.65 Billion INR | 1.65% |
| 2017 Q3 | 767.97 Million INR | 0.0% |
| 2016 Q1 | 615.74 Million INR | -12.91% |
| 2016 Q3 | 715.25 Million INR | -0.91% |
| 2016 Q2 | 721.79 Million INR | 17.22% |
| 2016 Q4 | 581.04 Million INR | -18.76% |
| 2016 FY | 2.61 Billion INR | -14.18% |
| 2015 FY | 3.04 Billion INR | -27.05% |
| 2015 Q2 | 797.03 Million INR | -2.18% |
| 2015 Q4 | 707.02 Million INR | -3.98% |
| 2015 Q3 | 736.29 Million INR | -7.62% |
| 2015 Q1 | 814.8 Million INR | 3.41% |
| 2014 Q2 | 940.1 Million INR | -47.23% |
| 2014 FY | 4.17 Billion INR | -26.79% |
| 2014 Q4 | 787.91 Million INR | 19.01% |
| 2014 Q3 | 662.08 Million INR | -29.57% |
| 2014 Q1 | 1.78 Billion INR | 51.71% |
| 2013 Q2 | 2.07 Billion INR | 49.04% |
| 2013 FY | 5.69 Billion INR | 44.94% |
| 2013 Q1 | 1.39 Billion INR | 5.79% |
| 2013 Q3 | 1.05 Billion INR | -49.0% |
| 2013 Q4 | 1.17 Billion INR | 11.01% |
| 2012 Q4 | 1.31 Billion INR | 34.21% |
| 2012 FY | 3.93 Billion INR | 0.0% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q2 | 1.63 Billion INR | 0.0% |
| 2012 Q3 | 980.15 Million INR | -40.07% |
| 2010 FY | 8.76 Billion INR | 27.13% |
| 2009 FY | 6.89 Billion INR | 16.15% |
| 2008 FY | 5.93 Billion INR | 14.32% |
| 2007 FY | 5.19 Billion INR | 36.73% |
| 2006 FY | 3.79 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Achyut Healthcare Limited | 61.36 Million INR | -8087.653% |
| Ajanta Pharma Limited | 42.08 Billion INR | 88.061% |
| Alkem Laboratories Limited | 126.67 Billion INR | 96.033% |
| Alpa Laboratories Limited | 1.08 Billion INR | -362.086% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 91.779% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 61.215% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 98.25% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -6.136% |
| Brooks Laboratories Limited | 794.86 Million INR | -532.146% |
| Divi's Laboratories Limited | 78.45 Billion INR | 93.595% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.2% |
| Eris Lifesciences Limited | 20.09 Billion INR | 74.991% |
| FDC Limited | 19.42 Billion INR | 74.139% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 95.747% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 77.993% |
| Granules India Limited | 45.06 Billion INR | 88.85% |
| Gufic Biosciences Limited | 8.06 Billion INR | 37.71% |
| Hester Biosciences Limited | 3.04 Billion INR | -64.989% |
| Indoco Remedies Limited | 17.89 Billion INR | 71.921% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 60.772% |
| Ipca Laboratories Limited | 76.22 Billion INR | 93.408% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -140.759% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -896.535% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -381.591% |
| Laurus Labs Limited | 50.01 Billion INR | 89.954% |
| Lupin Limited | 200.1 Billion INR | 97.489% |
| Mankind Pharma Limited | 103.34 Billion INR | 95.138% |
| Medicamen Biotech Limited | 1.79 Billion INR | -180.229% |
| Medico Remedies Limited | 1.44 Billion INR | -246.719% |
| Megasoft Limited | 373.95 Million INR | -1243.666% |
| NATCO Pharma Limited | 40.02 Billion INR | 87.445% |
| Piramal Pharma Limited | 81.71 Billion INR | 93.851% |
| Sigachi Industries Limited | 3.98 Billion INR | -25.946% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -565.122% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 98.964% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 52.208% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -93.821% |
| Unichem Laboratories Limited | 16.57 Billion INR | 69.684% |
| Windlas Biotech Limited | 6.3 Billion INR | 20.364% |
| ZIM Laboratories Limited | 3.67 Billion INR | -36.754% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 97.358% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 34.765% |
| RPG Life Sciences Limited | 5.82 Billion INR | 13.673% |
| Wanbury Limited | 5.75 Billion INR | 12.713% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 56.355% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -19.286% |
| Bal Pharma Limited | 3.39 Billion INR | -48.125% |
| Strides Pharma Science Limited | 40.51 Billion INR | 87.597% |
| Venus Remedies Limited | 5.91 Billion INR | 15.045% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 72.324% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 70.164% |
| Shilpa Medicare Limited | 11.51 Billion INR | 56.368% |
| Aarti Drugs Limited | 25.28 Billion INR | 80.128% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 76.287% |
| Suven Life Sciences Limited | 116.92 Million INR | -4197.207% |
| Valiant Laboratories Limited | 1.82 Billion INR | -175.995% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 85.579% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 59.426% |
| Themis Medicare Limited | 3.81 Billion INR | -31.619% |
| Hikal Limited | 17.84 Billion INR | 71.844% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 95.262% |
| Sequent Scientific Limited | 13.69 Billion INR | 63.316% |
| Novartis India Limited | 3.35 Billion INR | -49.959% |
| Wockhardt Limited | 27.89 Billion INR | 81.984% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 92.504% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -1155.063% |
| Neuland Laboratories Limited | 15.58 Billion INR | 67.761% |
| Morepen Laboratories Limited | 17.01 Billion INR | 70.476% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -225.491% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -36.32% |